Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (421-430 of 483) with videos related to

Pageof 49
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2024
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy TrialVida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
British Journal of Cancer|March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Hemasphere|April 25, 2025
Comparing functional and genomic-based precision medicine in blood cancer patientsLukas Kazianka, Alexander Pichler, Christiane Agreiter, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
The New England Journal of Medicine|September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Haematologica|July 4, 2020
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidityJulia C Gutjahr, Elisabeth Bayer, Xiaobing Yu, et al.
Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Pageof 49

Showing results (421-430 of 483) with videos related to

Sort By:
Pageof 49
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2024
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy TrialVida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
British Journal of Cancer|March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Hemasphere|April 25, 2025
Comparing functional and genomic-based precision medicine in blood cancer patientsLukas Kazianka, Alexander Pichler, Christiane Agreiter, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
The New England Journal of Medicine|September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Haematologica|July 4, 2020
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidityJulia C Gutjahr, Elisabeth Bayer, Xiaobing Yu, et al.
Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Pageof 49